Saturday 17 October 2026
Export MNTRQ’s income statement to Excel — free account
9 Meters Biopharma, Inc.
MNTRQ Healthcare Biotechnology
Follow MNTRQ
9 Meters Biopharma, Inc. (MNTRQ) EV/Sales
As of 26 September 2023, 9 Meters Biopharma, Inc. (MNTRQ) trades at a EV/Sales of −0.5×. Over the past ten years it has ranged from −0.6× (September 2023) to 237× (April 2018); the current reading is higher than 2% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2016 | 2.1× | 16.38% |
| FY2015 | 1.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2016 | 2.1× | 4.95% |
| Sep 2016 | 2.0× | 10.89% |
| Jun 2016 | 1.8× | 0.00% |
| Mar 2016 | 1.8× | 0.00% |
| 4 more quarters | Free account |
Against its own ten years
Low −0.6×
High 237×
Ten-year median
12.2×
Current reading's percentile
2
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LYRA Lyra Therapeutics, Inc. compare | −39.2× |
| MNTRQ 9 Meters Biopharma, Inc. | −0.5× |
| CRIS Curis, Inc. compare | −0.4× |
| BBLG Bone Biologics Corp. compare | n/m |
| PTIX Atrinsic Inc. compare | n/m |
| ZVSA ZyVersa Therapeutics, Inc. compare | n/m |
| CYTOF Altamira Therapeutics Ltd. compare | n/m |
| SPRC SciSparc Ltd. compare | n/m |
| BPTH Bio-Path Holdings, Inc. compare | n/m |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)